Evidence map›Paper›PMID 26172508›Full record

ArticleArchives of pathology & laboratory medicine2015

MicroRNA-375 Suppresses Extracellular Matrix Degradation and Invadopodial Activity in Head and Neck Squamous Cell Carcinoma.

Lizandra Jimenez, Ved P Sharma, John Condeelis, Thomas Harris, Thomas J Ow, Michael B Prystowsky, Geoffrey Childs, Jeffrey E Segall

Open access · bronzeAbstract read
In one paragraph

Article in Archives of pathology & laboratory medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Picrasidine J, a Dimeric β-Carboline-Type Alkaloid fromInternational journal of molecular sciences · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Lizandra Jimenez
Ved P Sharma
John Condeelis
Thomas Harris
Thomas J Ow
Michael B Prystowsky
Geoffrey Childs
Jeffrey E SegallFrom the Departments of Pathology (Ms Jimenez and Drs Harris, Ow, Prystowsky, Childs, and Segall) and Anatomy & Structural Biology (Ms Jimenez and Drs Sharma, Condeelis, and Segall), Albert Einstein College of Medicine, Bronx, New York.
Yeshiva University · US

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2M
Tumor Progression and MetastasisP01CA100324 · NCI · YESHIVA UNIVERSITY · PI CONDEELIS, JOHN S · 2003 to 2018
$30.0M
Signal transduction regulating tumor cell disseminationR01CA150344 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CONDEELIS, JOHN S · 2010 to 2020
$3.7M
ERBB1 AND ERBB2 IN TUMOR MOTILITY AND METASTASISR01CA077522 · NCI · YESHIVA UNIVERSITY · PI SEGALL, JEFFREY E · 2000 to 2011
$3.0M
Role of miRNA-375 in Invasive Phenotype of Head and Neck Squamous Cell CarcinomaF31CA168337 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JIMENEZ, LIZANDRA · 2012 to 2014
$195k
NCI NIH HHS CA100324NCI NIH HHS CA150344NCI NIH HHS CA168337NCI NIH HHS CA77522NCI NIH HHS F31 CA168337NCI NIH HHS P01 CA100324NCI NIH HHS P30 CA013330NCI NIH HHS R01 CA077522NCI NIH HHS R01 CA150344PHS HHS KG111405
6 · The paper itself

Abstract

contextHead and neck squamous cell carcinoma (HNSCC) is a highly invasive cancer with an association with locoregional recurrence and lymph node metastasis. We have previously reported that low microRNA-375 (miR-375) expression levels correlate with poor patient survival, increased locoregional recurrence, and distant metastasis. Increasing miR-375 expression in HNSCC cell lines to levels found in normal cells results in suppressed invasive properties. HNSCC invasion is mediated in part by invadopodia-associated degradation of the extracellular matrix.

objectiveTo determine whether elevated miR-375 expression in HNSCC cell lines also affects invadopodia formation and activity.

designFor evaluation of the matrix degradation properties of the HNSCC lines, an invadopodial matrix degradation assay was used. The total protein levels of invadopodia-associated proteins were measured by Western blot analyses. Immunoprecipitation experiments were conducted to evaluate the tyrosine phosphorylation state of cortactin. Human protease arrays were used for the detection of the secreted proteases. Quantitative real time-polymerase chain reaction measurements were used to evaluate the messenger RNA (mRNA) expression of the commonly regulated proteases.

resultsIncreased miR-375 expression in HNSCC cells suppresses extracellular matrix degradation and reduces the number of mature invadopodia. Higher miR-375 expression does not reduce cellular levels of selected invadopodia-associated proteins, nor is tyrosine phosphorylation of cortactin altered. However, HNSCC cells with higher miR-375 expression had significant reductions in the mRNA expression levels and secreted levels of specific proteases.

conclusionsMicroRNA-375 regulates invadopodia maturation and function potentially by suppressing the expression and secretion of proteases.

Indexed as

Gene Expression Regulation, NeoplasticBlotting, WesternCarcinoma, Squamous CellCell Line, TumorCell Surface ExtensionsCortactinEndopeptidasesExtracellular MatrixHead and Neck NeoplasmsHumansKallikreinsMatrix Metalloproteinase 9MicroRNAsProtein Array AnalysisProtein BindingProtein Interaction MapsCortactinEndopeptidasesKallikreinsKLK10 protein, humanKLK6 protein, humanMatrix Metalloproteinase 9MicroRNAsMIRN375 microRNA, humanMMP9 protein, humanProteomeSerine Endopeptidases

Identifiers

PMID26172508
PMCPMC4628565
OpenAlexW3125474606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.